Decorative image

Diagnosing phaeochromocytomas

There are different tests to diagnose phaeochromocytomas. These include blood and urine tests, CT, MRI and PET scans, and a type of scan called an MIBG scan.

Diagnosing phaeochromocytoma can be difficult as the symptoms are vague and can be caused by a number of other more common conditions.

Your GP will refer you to a specialist for tests if you have symptoms that could be caused by phaeochromocytoma. You might have some of the following tests.

Blood and urine tests

Doctors measure the amount of metanephrines in your urine and sometimes your blood. Metanephrines are the products made by the body when it breaks down the hormones adrenaline and noradrenaline.

Phaeochromocytomas can make large amounts of these hormones, which means the level of metanephrines in your blood and urine are higher than normal. The urine test is usually collected over 24 hours to give a more accurate result.

Before these tests, your doctor will advise you of food and drink that you should avoid for a few days. These include coffee, tea, chocolate, bananas and citrus fruits. This is because they can affect your test results. Your doctor will also tell you if there are any medicines that you need to stop taking before and during the tests.

CT scan

A CT scanner takes x-rays from different angles to form a detailed image of the inside of your body. This can show doctors where a tumour is, how big it is and whether it has spread anywhere else. 

MRI scan

An MRI scanner uses magnetism rather than x-rays to build up a picture of the inside of your body. MRI scans are especially good at showing up soft tissue in the body.

MIBG scan

This is a specialised scan that doctors might use to diagnose phaeochromocytoma and to see if it has spread to other parts of your body. You have the scan in the nuclear medicine department at the hospital.

First, you have an injection of a small amount of mildly radioactive chemical called MIBG (meta-iodo-benzyl-guanidine). You have your scan 4 hours later. The phaeochromocytoma cells take up the MIBG, which then show up on the scan. You may have to go back to the hospital the next day to have another scan.

After you have had the radioactive injection, you need to drink plenty and go to the toilet regularly. This is to help flush out the excess MIBG and make the images on the scan clearer.

After the injection and for the rest of the day after your scan, you should avoid long periods of close contact with pregnant women and children.

The team at your hospital will give you specific advice about this.

PET scan


In some hospitals, instead of an MIBG scan, you may have a DOTATATE PET scan. This helps to diagnose phaeochromocytoma and to see if it has spread. With this type of scan you have a radioactive drug called 68-Ga-DOTATATE. This drug binds to certain receptors on tumour cells, and shows up on the scan.

After having the injection of 68-Ga-DOTATATE into a vein in your arm, you have to wait 60 to 90 minutes before having a PET scan or a PET-CT scan.

For the rest of the day after having the radioactive injection, you should avoid long periods of close contact with children and pregnant women. The team in the nuclear medicine department will give you advice about this.

FDG PET scan

This is the most common type of PET scan. The doctors use a different radioactive drug (tracer) called fluorodeoxyglucose (FDG). You might have this type of PET scan before your operation. 

Last reviewed: 
22 Jun 2018
  • Cancer and its management (6th edition)
    J Tobias and R Hochhauser
    Wiley Blackwell, 2010

  • Diagnosis and management of pheochromocytoma: a practical guide to clinicians
    JM. Pappachan (and others)
    Current Hypertension Reports. 2014 Jul;16(7):442   

  • Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment
    VL. Martucci VL and K. Pacak
    Current Problems in Cancer. 2014 Jan-Feb;38 (1):7-41    

  • Principles and practice of oncology (10th edition)
    VT. De lVita, S. Hellman, and SA.Rosenberg
    Walters Kluwer, 2015

  • Adrenal cancer: ESMO Clinical Practice Guidelines
    A. Berruti and others
    Annals of Oncology 2012; 23 (Suppl 7): vii131-vii138.